Glenn D Crater (Glenn Crater)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Venues

Canadian respiratory journal

Therapeutic advances in respiratory disease

Respiratory research

Theravance Biopharma US

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Theravance Biopharma US

United States

Respiratory Portfolio Head :: Development

Publications

Jill A Ohar, Donald A Mahler, Gabrielle N Davis, David A Lombardi, Edmund J Moran, Glenn D Crater
Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow. Canadian respiratory journal 2024 (2024)
Jill A Ohar, Donald A Mahler, Gabrielle N Davis, David A Lombardi, Edmund J Moran, Glenn D Crater
Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow. Canadian respiratory journal 2024 (2024)
Jill A Ohar, Donald A Mahler, Gabrielle N Davis, David A Lombardi, Edmund J Moran, Glenn D Crater
Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow. Canadian respiratory journal 2024 (2024)
Glenn D Crater, Karmon Johnson, Jonathan Ward, Jan De Backer
Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease. Therapeutic advances in respiratory disease 16 (2022)
Sanjay Sethi, James F Donohue, Gary T Ferguson, Chris N Barnes, Glenn D Crater
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Therapeutic advances in respiratory disease 14 (2021)
James F Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N Barnes, Edmund J Moran, Glenn D Crater
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). Respiratory research 20 (1) (2019)

Glenn D Crater.css-eqlu8i{font-size:small;padding-left:4px;} (Glenn Crater)

Publication Activity (10 Years)

Top Topics

Top Venues

Glenn D Crater (Glenn Crater)